NCT03831295View on ClinicalTrials.gov

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

October 4, 2021

Study Completion Date

October 4, 2021

Conditions

Advanced Malignant Solid NeoplasmExtracranial Solid NeoplasmMetastatic Malignant Solid Neoplasm

Interventions

BIOLOGICAL

Anti-OX40 Antibody BMS 986178

Given IT or IV

DRUG

TLR9 Agonist SD-101

Given IT

Trial Locations (1)

94304

Stanford Cancer Institute Palo Alto, Palo Alto

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Ronald Levy

OTHER